EU and US could reach trade deal this weekend - Reuters
Stifel, a financial services company, has adjusted its price target for Cerus (NASDAQ:CERS) Corporation (NASDAQ: CERS), a biomedical products company, to $3.00 from the previous $6.00, while still recommending a Buy rating for the stock.
The revision followed an announcement that the European Union's review of Cerus's INTERCEPT Red Blood Cells (RBC) did not result in approval, as additional data was requested.
The company stated that it is still confident in the INTERCEPT program's future and plans to pursue approval with a new submission. However, due to the EU's decision, the expected timeline for approval has been extended by more than a year. This development was considered a setback, especially since the EU RBC program was seen as a significant potential driver for Cerus's growth.
Despite the negative news, Stifel's analysis suggests that the market has already factored in the challenges associated with the EU RBC program into Cerus's stock price. Furthermore, Stifel has removed an additional $1.00 per share from its valuation to account for increased risks to the U.S. RBC program.
In other recent news, Cerus Corporation has seen several developments that may interest investors. The biomedical company's annual product revenue guidance for 2024 has been revised upwards to between $175 million and $178 million, marking a significant increase from the previous range of $172 million to $175 million. This adjustment is largely due to a 16% year-over-year growth in product revenue, which totaled $45.1 million, primarily driven by the increased use of Cerus' INTERCEPT blood system.
In addition to its financial performance, Cerus has secured a contract with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $248 million. This contract will support the development of its INTERCEPT red blood cell (RBC) system in the United States, from U.S. Phase 3 studies through to potential approval and commercialization.
However, Cerus recently faced a setback when the European Union's review of its INTERCEPT RBC product concluded without granting approval, citing the need for additional data. Despite this, Cerus remains optimistic about the future of its INTERCEPT program and plans to pursue approval with a new submission.
On the analyst front, Stifel has adjusted its price target for Cerus to $3.00, down from the previous $6.00, but maintains a Buy rating on the stock. Meanwhile, BTIG analysts have reiterated a Neutral rating for Cerus, following the company's stronger-than-expected performance in the second quarter.
InvestingPro Insights
Recent InvestingPro data provides additional context to Cerus Corporation's financial situation. With a market capitalization of $333.53 million, the company's revenue for the last twelve months as of Q2 2024 stood at $169.98 million, showing a growth of 10.79%. This growth trend is further emphasized by the quarterly revenue growth of 16.02% in Q2 2024, indicating some positive momentum despite the regulatory setback in Europe.
InvestingPro Tips highlight that Cerus operates with a moderate level of debt and its liquid assets exceed short-term obligations, which could provide some financial flexibility as the company navigates the extended timeline for EU approval. However, it's important to note that Cerus is not currently profitable, with a negative operating income of $14.48 million for the last twelve months.
The stock's Price to Book ratio of 6.74 suggests that investors are still placing a premium on the company's assets, possibly due to future growth expectations. This aligns with Stifel's maintained Buy rating, despite the lowered price target.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips for Cerus Corporation, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.